Skip to content

Registry for Pulmonary Hypertension Due to Left Heart Disease in China

National, Prospective, Multicenter,Observational Registry Study on Pulmonary Hypertension Due to Left Heart Disease in China

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT02164526
Enrollment
520
Registered
2014-06-16
Start date
2013-01-31
Completion date
2018-12-31
Last updated
2017-06-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pulmonary Hypertension Due to Left Heart Disease

Keywords

Pulmonary Hypertension, Left Heart Disease, Heart failure, Registry, China

Brief summary

Left heart disease is the main cause of pulmonary hypertension. With the advent of the aging society, chronic heart failure has become a global public health problem. Therefore the prevalence of pulmonary hypertension due to the left heart disease is increasing. However, there is no research on the prevalence of pulmonary hypertension due to the left heart disease in China. Therefore, the aim of the present study was to describe real-world outcome of Chinese patients with pulmonary hypertension due to the left heart disease and identify factors that may predict outcome. Our study will profile the demographics, clinical course, treatments, and outcomes of pulmonary hypertension due to the left heart disease in China.

Interventions

Routine therapy

Sponsors

Chinese Academy of Medical Sciences, Fuwai Hospital
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to 80 Years
Healthy volunteers
No

Inclusion criteria

* Pulmonary Hypertension due to left heart disease

Exclusion criteria

* Other forms of Pulmonary Hypertension * Heart failure due to valvular heart disease * Hypertrophic obstructive cardiomyopathy * Right ventricular outflow tract stenosis * Pericardial disease * Patients with chronic lung disease

Design outcomes

Primary

MeasureTime frame
All cause deathup to 5 years

Countries

China

Contacts

Primary ContactJianguo He, MD
hejianguofw@gmail.com861088398826

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 13, 2026